Therefore, any defect in one of these DNA repair pathways, particularly HR and BER, can increase the efficacy of platinum salts, which is consistent with our findings that the inhibition of both CDK4/6 and PARP by ZC-22 greatly improves the response of breast and ovarian cancer to cisplatin treatment. The gene discussed is PARP1; the disease is ovarian carcinoma.